A new analysis argues that for US rare-disease developers, FDA alignment should be treated as an initial step rather than a finished rare-disease strategy for Europe. The piece emphasizes how decisions around clinical evidence, patient selection, and regulatory feedback can affect European planning well before an EU marketing authorization application. For biotech teams targeting both regions, the report highlights the operational reality that evidence requirements and interaction timelines differ, creating a need for structured parallel regulatory engagement.